FCA
GILD icon

Fortis Capital Advisors’s Gilead Sciences GILD Stock Holding History

Fortis Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
3,369
+320
+10% +$42.2K 0.05% 264
2026
Q1 		$425K Buy
3,049
+1,182
+63% +$166K 0.06% 252
2025
Q4 		$229K Buy
+1,867
New +$227K 0.03% 279
2023
Q2 		– Sell
-1,999
Closed -$166K – 313
2023
Q1 		$166K Sell
1,999
-3,657
-65% -$303K 0.09% 128
2022
Q4 		$486K Buy
+5,656
New +$448K 0.29% 53

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fortis Capital Advisors's GILD Position: Q2 2026 in Review

Fortis Capital Advisors increased its Gilead Sciences (GILD) stake by 10% in Q2 2026, buying an estimated $42.2K and bringing the position to 3,369 shares worth $426K. The position accounts for 0.05% of the portfolio, ranked #264.

Fortis Capital Advisors first reported a position in GILD in Q4 2022 and has held it in 5 quarters since. The position peaked at $486K in Q4 2022. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Fortis Capital Advisors held 3,369 shares of Gilead Sciences worth $426K as of Q2 2026.
  • Fortis Capital Advisors bought 320 Gilead Sciences shares in Q2 2026, an estimated $42.2K.
  • Gilead Sciences made up 0.05% of Fortis Capital Advisors's portfolio in Q2 2026, its #264 holding.
  • Fortis Capital Advisors first reported a position in Gilead Sciences in Q4 2022 and has held it in 5 quarters since.
  • Fortis Capital Advisors's Gilead Sciences position peaked at $486K in Q4 2022.
  • 2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Fortis Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.